T. Rowe Price Associates’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-41,454
| Closed | -$49K | – | 3136 |
|
|
2025
Q2 | $49K | Sell |
41,454
-28,231
| -41% | -$37.2K | ﹤0.01% | 3011 |
|
|
2025
Q1 | $111K | Sell |
69,685
-910,170
| -93% | -$1.96M | ﹤0.01% | 2800 |
|
|
2024
Q4 | $2.97M | Sell |
979,855
-57,056
| -6% | -$187K | ﹤0.01% | 1461 |
|
|
2024
Q3 | $3.82M | Buy |
1,036,911
+113,010
| +12% | +$411K | ﹤0.01% | 1380 |
|
|
2024
Q2 | $3.78M | Sell |
923,901
-2,565,808
| -74% | -$28.7M | ﹤0.01% | 1308 |
|
|
2024
Q1 | $55M | Buy |
3,489,709
+585,644
| +20% | +$8.06M | 0.01% | 708 |
|
|
2023
Q4 | $44M | Buy |
2,904,065
+188,466
| +7% | +$2.75M | 0.01% | 747 |
|
|
2023
Q3 | $54.5M | Buy |
2,715,599
+31,247
| +1% | +$793K | 0.01% | 653 |
|
|
2023
Q2 | $75.7M | Buy |
2,684,352
+484,183
| +22% | +$11.6M | 0.01% | 588 |
|
|
2023
Q1 | $37.8M | Buy |
2,200,169
+23,469
| +1% | +$475K | 0.01% | 759 |
|
|
2022
Q4 | $43.8M | Sell |
2,176,700
-41,040
| -2% | -$883K | 0.01% | 698 |
|
|
2022
Q3 | $48M | Sell |
2,217,740
-2,080,811
| -48% | -$56.9M | 0.01% | 658 |
|
|
2022
Q2 | $121M | Buy |
4,298,551
+100,371
| +2% | +$2.66M | 0.02% | 609 |
|
|
2022
Q1 | $194M | Sell |
4,198,180
-184,701
| -4% | -$9.96M | 0.02% | 534 |
|
|
2021
Q4 | $368M | Buy |
4,382,881
+652,456
| +17% | +$50.5M | 0.03% | 408 |
|
|
2021
Q3 | $249M | Buy |
3,730,425
+470,857
| +14% | +$27.2M | 0.02% | 476 |
|
|
2021
Q2 | $173M | Buy |
3,259,568
+2,175,322
| +201% | +$117M | 0.02% | 604 |
|
|
2021
Q1 | $47M | Sell |
1,084,246
-9,780
| -0.9% | -$421K | ﹤0.01% | 1026 |
|
|
2020
Q4 | $56.8M | Sell |
1,094,026
-11,994
| -1% | -$541K | 0.01% | 919 |
|
|
2020
Q3 | $36.2M | Sell |
1,106,020
-81,546
| -7% | -$2.86M | ﹤0.01% | 977 |
|
|
2020
Q2 | $57M | Buy |
+1,187,566
| New | +$45.5M | 0.01% | 808 |
|
Other funds holding ZNTL
MCMC
TCM
